{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:43:06Z","timestamp":1789753386957,"version":"4.0.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jinf.2025.106487","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T19:14:40Z","timestamp":1744658080000},"page":"106487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Continuous versus intermittent bolus dosing of beta-lactam antibiotics in a South African multi-disciplinary intensive care unit: A randomized controlled trial"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3105-3522","authenticated-orcid":false,"given":"Ayesha Bibi","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Hafiz","family":"Abdul-Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2093-123X","authenticated-orcid":false,"given":"Lucy","family":"Hindle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5965-9876","authenticated-orcid":false,"given":"Jeffrey","family":"Lipman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fetolang","family":"Simelela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-1518","authenticated-orcid":false,"given":"Shahed","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2025.106487_bib1","unstructured":"Centers for Disease Control and Prevention (CDC). Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019. Available from: https:\/\/www.cdc.gov\/antimicrobial-resistance\/data-research\/threats\/index.html."},{"issue":"12","key":"10.1016\/j.jinf.2025.106487_bib2","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: Retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.jinf.2025.106487_bib3","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1097\/CCM.0000000000005357","article-title":"Executive summary: Surviving sepsis campaign: International Guidelines for the Management of Sepsis and Septic Shock 2021","volume":"49","author":"Evans","year":"2021","journal-title":"Crit Care Med"},{"issue":"8","key":"10.1016\/j.jinf.2025.106487_bib4","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jinf.2025.106487_bib5","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.3390\/jcm12093188","article-title":"2023 Update on sepsis and septic shock in adult patients: Management in the Emergency Department","volume":"12","author":"Guarino","year":"2023","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.jinf.2025.106487_bib6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.7196\/SAJCC.2021.v37i3.495","article-title":"A retrospective evaluation of a multiplex polymerase chain reaction test directly applied to blood for the management of sepsis in the critically ill","volume":"37","author":"Omar","year":"2021","journal-title":"South Afr J Crit Care"},{"issue":"2","key":"10.1016\/j.jinf.2025.106487_bib7","article-title":"Bed occupancy and nosocomial infections in the intensive care unit: A retrospective observational study in a tertiary hospital","volume":"40","author":"Wilson","year":"2024","journal-title":"South Afr J Crit Care"},{"issue":"5","key":"10.1016\/j.jinf.2025.106487_bib8","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/MCC.0000000000001074","article-title":"Severe infections caused by difficult-to-treat Gram-negative bacteria","volume":"29","author":"Dettori","year":"2023","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.jinf.2025.106487_bib9","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3390\/antibiotics12030568","article-title":"Update on therapeutic drug monitoring of beta-lactam antibiotics in critically ill patients\u2014A narrative review","volume":"12","author":"Sta\u0161ek","year":"2023","journal-title":"Antibiotics"},{"issue":"3","key":"10.1016\/j.jinf.2025.106487_bib10","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","article-title":"Pharmacokinetic issues for antibiotics in the critically ill patient","volume":"37","author":"Roberts","year":"2009","journal-title":"Crit Care Med"},{"issue":"2","key":"10.1016\/j.jinf.2025.106487_bib11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/1751143714564816","article-title":"Pharmacokinetic considerations and dosing strategies of antibiotics in the critically ill patient","volume":"16","author":"Shah","year":"2015","journal-title":"J Intensive Care Soc"},{"issue":"1","key":"10.1016\/j.jinf.2025.106487_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/srep37853","article-title":"Optimising antibiotic usage to treat bacterial infections","volume":"6","author":"Paterson","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jinf.2025.106487_bib13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1055\/s-0034-1398490","article-title":"Applying pharmacokinetic\/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development","volume":"36","author":"Abdul-Aziz","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.jinf.2025.106487_bib14","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00134-015-4188-0","article-title":"Beta-lactam infusion in severe sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis","volume":"42","author":"Abdul-Aziz","year":"2016","journal-title":"Intensive Care Med"},{"issue":"2","key":"10.1016\/j.jinf.2025.106487_bib15","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/cid\/cis856","article-title":"Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial","volume":"56","author":"Dulhunty","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.jinf.2025.106487_bib16","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.4103\/0366-6999.205859","article-title":"Pharmacokinetic and pharmacodynamic efficacies of continuous versus intermittent administration of meropenem in patients with severe sepsis and septic shock: A prospective randomized pilot study","volume":"130","author":"Zhao","year":"2017","journal-title":"Chin Med J (Engl)"},{"issue":"11","key":"10.1016\/j.jinf.2025.106487_bib17","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s40262-019-00791-z","article-title":"What antibiotic exposures are required to suppress the emergence of resistance for Gram-negative bacteria? A systematic review","volume":"58","author":"Sumi","year":"2019","journal-title":"Clin Pharm"},{"issue":"2","key":"10.1016\/j.jinf.2025.106487_bib18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jama.2023.10598","article-title":"Continuous vs intermittent meropenem administration in critically ill patients with sepsis: The MERCY randomized clinical trial","volume":"330","author":"Monti","year":"2023","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.jinf.2025.106487_bib19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/jama.2024.9779","article-title":"Continuous vs intermittent \u03b2-lactam antibiotic infusions in critically ill patients with sepsis: The BLING III randomized clinical trial","volume":"332","author":"Dulhunty","year":"2024","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jinf.2025.106487_bib20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"10.1016\/j.jinf.2025.106487_bib21","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1001\/jama.2024.9803","article-title":"Prolonged vs intermittent infusions of \u03b2-lactam antibiotics in adults with sepsis or septic shock: A systematic review and meta-analysis","volume":"332","author":"Abdul-Aziz","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.jinf.2025.106487_bib22","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1164\/rccm.201505-0857OC","article-title":"A multicenter randomized trial of continuous versus intermittent \u03b2-lactam infusion in severe sepsis","volume":"192","author":"Dulhunty","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jinf.2025.106487_bib23","doi-asserted-by":"crossref","DOI":"10.1186\/cc11405","article-title":"Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial","volume":"16","author":"Chytra","year":"2012","journal-title":"Crit Care"},{"key":"10.1016\/j.jinf.2025.106487_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcrc.2022.154170","article-title":"The clinical and paraclinical effectiveness of four-hour infusion vs. half-hour infusion of high-dose ampicillin-sulbactam in treatment of critically ill patients with sepsis or septic shock: An assessor-blinded randomized clinical trial","volume":"73","author":"Mirjalili","year":"2023","journal-title":"J Crit Care"},{"issue":"1","key":"10.1016\/j.jinf.2025.106487_bib25","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13054-021-03592-8","article-title":"Comparison of culture-negative and culture-positive sepsis or septic shock: a systematic review and meta-analysis","volume":"25","author":"Li","year":"2021","journal-title":"Crit Care"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445325000817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445325000817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T13:16:09Z","timestamp":1745846169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445325000817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0163445325000817"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2025.106487","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Continuous versus intermittent bolus dosing of beta-lactam antibiotics in a South African multi-disciplinary intensive care unit: A randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2025.106487","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106487"}}